• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Venture Capital Matters

#VentureCapital: VC meets social media

  • Pitch a Startup
    • Make a Contribution
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
  • Contact

Philogen Announces €62 Million Financing Round €62M funding to be used to progress wholly-owned pipeline products through clinical development and expand manufacturing activities

May 13, 2019 By 3v.org Leave a Comment

Philogen S.p.A (or the “Company”), a clinical-stage biotechnology company focused on antibody-based therapeutics, today is pleased to announce a €62 million financing round from current and new private investors. The €62 million financing will be used to progress Philogen’s wholly-owned pipeline products through clinical development and provide working capital whilst the bulk of the pipeline continues to progress in partnership with large pharmaceutical companies. The capital increase will also be used to expand Philogen’s GMP facilities, enabling large scale production of antibody products.

Philogen’s therapeutic approach is based on the antibody-mediated delivery of bioactive payloads to the site of disease helping spare normal tissues. In particular, cytokine payloads hold promises for treatment of serious conditions, through a selective modulation of immune system activity. The disease targeting ability of Philogen’s antibodies, that recognize specific targets expressed in the majority of solid and liquid malignancies, have been extensively validated with nuclear medicine techniques in patients with cancer.

The Company currently has two products in Phase III development for oncological indications. Daromun is being investigated for the treatment of fully resectable Stage III B / C melanoma while Fibromun is being studied in metastatic soft tissue sarcoma. The pipeline is complemented by other products that are in Phase I or Phase II clinical trials.

In addition to its validating partnerships with big pharma, Philogen has a robust IP position with more than 40 international patent families and is a fully integrated company from discovery to GMP manufacturing and clinical trial execution.

Philogen also today announces the appointment of three new board members, Dr. Guido Guidi previously Head of Oncology Europe at Novartis, Dr. Roberto Marsella previously Director of Investments of Fondo Strategico Italiano / CDP Equity, now with Generali, and Dr. Roberto Ferraresi previously partner of PAI partners and currently CEO of The Equity Club.

“Philogen uses state of the art discovery technology to innovate ligand based pharmacodelivery and is committed to the engineering of superior antibody cytokine fusions.” said Dr. Duccio Neri, Chief Executive Officer of Philogen. “This financing will help us execute our strategy and develop innovative biopharmaceuticals for the treatment of diseases which urgently better therapeutic modalities. We welcome our three new Board members to Philogen and look forward to their valuable contributions at this exciting time in our Company’s evolution.”

Leopoldo Zambeletti acted as advisor to Philogen in the financing.

About Philogen
Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned and has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com.

Related

Filed Under: PR

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Posh raises $3.8M seed round to automate EV battery recycling
  • Strapi Secures $31 Million in Series B Funding to Further Develop Open Source Headless Content Management System and Deliver Cloud Platform
  • Salesroom Raises $8.5M to Bring Smart Video to Sales Meetings
  • Parallelz Raises $3M Pre-Seed Funding to Challenge App Store Monopoly
  • Appsmith Raises $41 Million to Scale Open Source Platform that Speeds Critical Internal App Development
  • Electric Hydrogen Secures $198M in Financing to Decarbonize Global Industries With Fossil-Free Hydrogen
  • Rivet Raises $20.5 Million Series B Led by Catalyst Investors
  • CloudNC raises $45m to deliver autonomous manufacturing
  • Platform.sh Raises $140 million in Series D Funding
  • Canditech raises $9 million seed round from Insight Partners and StageOne Ventures to create a world without resumes

Media Partners

  • VPNW
  • S3H
  • OPINT
  • Press Media Release
  • OSINT
  • Digital Market
  • Briefly
  • App Coding
  • API Coding
  • Blockchaining

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Defense Conferences
  • Cybersecurity Events
  • Event Calendar
  • Calendarial
  • Opinion
  • Domain Name for Business

Copyright © 2018 3V.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT